NCT04862767View on ClinicalTrials.gov

TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions
Solid Tumor
Interventions
DRUG

TASO-001((TGF-β2 targeting anti-sense oligonucleotide)

96 hour continuous infusion

COMBINATION_PRODUCT

Aldesleukin

SC, Bid

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Autotelicbio
All Listed Sponsors
lead

Autotelicbio

INDUSTRY